| abstract |
This application relates to oral taxane compositions and methods. The pharmaceutical composition comprises a taxane (eg, paclitaxel, docetaxel, cabazitaxel, larotaxel, otetaxel, and/or tesetaxel) in a mixture of first and second surfactants. The increase in absorbance of the taxane from the pharmaceutical composition is greater than the sum of the absorbance of docetaxel from the first or second surfactant. Absorption is especially enhanced when the weight ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 and the total surfactant weight does not exceed 98% of the total weight increase. Polysorbate 80, polysorbate 20, and caprylocaproylpolyoxyglycerides serve as suitable primary surfactants, while polysorbate 80 or polyethoxylated castor oil serve as suitable secondary surfactants agent. The stability of the pharmaceutical composition can be enhanced by further comprising a stabilizer such as citric acid and/or ascorbic acid. |